AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 699627
Drug: Dextropropoxyphene (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene (65 mg) plus paracetamol (650 mg) 3-times daily
Trial: 28562271
Drug: Perceived barriers
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived barriers (e.g., lack of knowing what to do in the event of pandemic influenza)
Trial: 26999839
Drug: ABNS+SS (Allergen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABNS+SS (Allergen Blocking Nasal Spray + Seawater Spray)
Trial: 26999839
Drug: SS (Seawater
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SS (Seawater Spray)
Trial: 19568030
Drug: Unstable surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unstable surface balance training (air-filled rubber disks, 5 weeks, thrice weekly sessions)
Trial: 14653285
Drug: Ultra‐Etch 35%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra‐Etch 35% phosphoric acid gel
Trial: 14653285
Drug: Ultra‐Etch AB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra‐Etch AB 35% phosphoric acid gel with cetylpyridinium chloride antimicrobial agent
Trial: 14653285
Drug: Ultra‐Etch 35%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra‐Etch 35% phosphoric acid gel followed by Concepsis chlorhexidine gluconate antimicrobial solution
Trial: 14653285
Drug: Ultra‐Etch 35%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra‐Etch 35% phosphoric acid gel followed by Consepsis Scrub chlorhexidine gluconate antimicrobial slurry
Trial: 14653285
Drug: No etchant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No etchant and/or cavity pre‐treatment
Trial: 11129093
Drug: Rifampicin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (600 mg/day) administered from day 15 to day 18
Trial: 3890229
Drug: Lymecycline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymecycline (300 mg bid for 7 days)
Trial: 26433040
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg orally 1 hour before general anesthesia
Trial: 18601757
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of ropivacaine (100 mL solution of ropivacaine in a concentration of 2 mg/mL) (Group A)
Trial: 18601757
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intravesical instillation and subepithelial injection of 2 mL (4 mg) at the site of biopsy (Group B)
Trial: 11470347
Drug: Quintuple buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quintuple buprenorphine dosing (5x daily maintenance dose)
Trial: 11470347
Drug: Sextuple buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sextuple buprenorphine dosing (6x daily maintenance dose)
Trial: 9347651
Drug: Standardized ginseng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized ginseng extract 150 mg per capsule, 2 capsules daily for 8 weeks
Trial: 27884916
Drug: Usual medical
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual medical treatments (tranexamic/mefenamic acid, combined oestrogen-progestogen, or progesterone alone)
Trial: 22682988
Drug: Treatment-as-usual (N=10)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (N=10)
Trial: 17053895
Drug: Artemether and
RxNorm normalized name: artemether and lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether and lumefantrine (AL) treatment
Trial: 12837873
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FP) 200 microg/day for 6 weeks
Trial: 10717490
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (ERT, conjugated equine estrogen 0.625 mg orally daily)
Trial: 10717490
Drug: Combined estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined estrogen and continuous progestogen therapy (HRT, 0.625 mg of conjugated equine estrogens plus medroxyprogesterone acetate 5 mg daily)
Trial: 8856585
Drug: Intravenous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atropine sulfate (0.04 mg/kg/day, increased by 0.01 mg/kg/day until vomiting ceased)
Trial: 8856585
Drug: Oral atropine
RxNorm normalized name: atropine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral atropine sulfate (twice the effective intravenous dose) continued for 2 weeks after intravenous treatment
Trial: 8856585
Drug: Ultrasonography after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonography after intravenous atropine treatment
Trial: 8856585
Drug: Intravenous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atropine sulfate
Trial: 30864528
Drug: New antiepileptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antiepileptic drugs (NADs)
Trial: 30044293
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of oral hypoglycemics (OHDs)
Trial: 30044293
Drug: Withholding oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withholding oral hypoglycemics (OHDs)
Trial: 24690440
Drug: Core vitrectomy
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Core vitrectomy additional to three times injections of ranibizumab (3x Rbz)
Trial: 20104770
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine 10 microg each time (group A)
Trial: 17502347
Drug: Refrigerator-stable formulation
RxNorm normalized name: Refrigerant 114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refrigerator-stable formulation of ProQuad
Trial: 17502347
Drug: Frozen formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frozen formulation of ProQuad
Trial: 14969836
Drug: IFN 3
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN 3 MIU daily for 4 weeks, followed by tiw up to 12 months
Trial: 14969836
Drug: IFN 3
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN 3 MIU daily for 12 weeks, followed by tiw up to 12 months
Trial: 11675061
Drug: LY334370 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY334370 20 mg
Trial: 11675061
Drug: LY334370 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY334370 60 mg
Trial: 11675061
Drug: LY334370 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY334370 200 mg
Trial: 3035849
Drug: Naloxone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (100 micrograms/kg bolus followed by 50 micrograms X kg‐1 X h‐1 infusion)
Trial: 3035849
Drug: Control (corresponding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (corresponding volume of preservatives as bolus followed by infusion of diluted preservatives)
Trial: 24091306
Drug: Short-term psychotherapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term psychotherapy (solution-focused or short-term psychodynamic)
Trial: 20869680
Drug: Sonographically guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonographically guided ACJ injections
Trial: 20869680
Drug: Palpation-guided ACJ
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palpation-guided ACJ injections
Trial: 14628190
Drug: Zydis Selegiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zydis Selegiline 10 mg
Trial: 14628190
Drug: Conventional selegiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional selegiline tablets 10 mg
Trial: 14628190
Drug: Zydis Selegiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zydis Selegiline 1.25 mg
Trial: 10590283
Drug: Azithromycin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1200 mg/week)
Trial: 8829718
Drug: Original trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original trial medication
Trial: 8829718
Drug: Continuous use
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous use of psychotropic medication during follow-up
Trial: 386061
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg twice a day
Trial: 386061
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg twice a day
Trial: 386061
Drug: Oxprenolol 80
RxNorm normalized name: oxprenolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol 80 mg twice a day
Trial: 386061
Drug: Oxprenolol 160
RxNorm normalized name: oxprenolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol 160 mg twice a day
Trial: 18180581
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment methods for cartilage defects, specific interventions not detailed, timing and methods of treatment unclear.
Trial: 18180581
Drug: Natural course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural course of cartilage defects, treatment methods not specified.
Trial: 14753327
Drug: Vitremer in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitremer in De‐Re‐ solutions
Trial: 9273875
Drug: 5 mg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/m3 zinc oxide
Trial: 9273875
Drug: 2.5 mg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/m3 zinc oxide
Trial: 7958542
Drug: Glibenclamide 1.75
RxNorm normalized name: Glibenclamide 1.75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide 1.75 mg
Trial: 7958542
Drug: Glibenclamide 3.5
RxNorm normalized name: Glibenclamide 3.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide 3.5 mg
Trial: 7958542
Drug: Glibenclamide 7.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide 7.0 mg
Trial: 7958542
Drug: AG 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG 1.0 mg
Trial: 7958542
Drug: AG 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG 2.0 mg
Trial: 7958542
Drug: AG 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG 4.0 mg
Trial: 7958542
Drug: Glibenclamide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (all doses)
Trial: 7958542
Drug: AG (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG (all doses)
Trial: 2885301
Drug: Propranolol (PROP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (PROP, 80 mg twice daily)
Trial: 2885301
Drug: Atenolol (ATEN,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (ATEN, 100 mg once a day)
Trial: 28454794
Drug: Intravascular ultrasound-guided
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular ultrasound-guided PCI with the novel everolimus-eluting platinum-chromium Synergy stent followed by 4 months of dual antiplatelet therapy (DAPT)
Trial: 19154471
Drug: bevacizumab (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bevacizumab (in combination with interferon)
Trial: 2510284
Drug: Rioprostil (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rioprostil (single oral dose)
Trial: 2510284
Drug: Rioprostil (repeated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rioprostil (repeated evening doses)
Trial: 26150444
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after concurrent chemoradiotherapy (CCRT) with the same agents.
Trial: 26150444
Drug: CCRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCRT with docetaxel (20 mg/m(2)) and cisplatin (20 mg/m(2)) administered weekly for 6 weeks.
Trial: 26150444
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy (CC) with docetaxel and cisplatin (DP) after CCRT.
Trial: 23194084
Drug: Dapagliflozin 2.5
RxNorm normalized name: dapagliflozin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 2.5 mg/day
Trial: 23194084
Drug: Dapagliflozin 5
RxNorm normalized name: dapagliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 5 mg/day
Trial: 11147379
Drug: Cisatracurium (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium (0.2 mg/kg) administered IV
Trial: 3531953
Drug: 100 IU
RxNorm normalized name: Vitamin E 100 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 IU of salmon calcitonin subcutaneously daily for 28 days
Trial: 3531953
Drug: Physiological solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological solution (placebo) administered daily for 28 days
Trial: 30409830
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (CYC) for 1 year in SLS I
Trial: 30409830
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (CYC) for 1 year followed by 1 year of placebo in SLS II
Trial: 24951020
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (60 mg/kg)
Trial: 24951020
Drug: Cryoprecipitate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryoprecipitate (10 mL/kg)
Trial: 22252356
Drug: ID diet
RxNorm normalized name: FREE AMINO ACID DIET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID diet (1,200 mg/hen per day)
Trial: 22252356
Drug: SPL diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPL diet (1,010 mg/hen per day)
Trial: 22252356
Drug: SP diet
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP diet (600 mg/hen per day)
Trial: 22252356
Drug: ID diet
RxNorm normalized name: FREE AMINO ACID DIET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID diet (1,010 mg/hen per day)
Trial: 22252356
Drug: IDL diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDL diet (1,200 mg/hen per day)
Trial: 20139218
Drug: Empirical antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antibiotics
Trial: 20139218
Drug: Empirical delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical delayed antibiotics (by 48 hours)
Trial: 20139218
Drug: Targeted antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted antibiotics based on high symptom score
Trial: 20139218
Drug: Targeted antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted antibiotics based on dipstick results
Trial: 20139218
Drug: Targeted antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted antibiotics based on midstream urine analysis
Trial: 8169337
Drug: Captopril, 25
RxNorm normalized name: Captopril, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril, 25 mg twice daily
Trial: 8826574
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid administration
Trial: 24276838
Drug: IV magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV magnesium sulfate (MgSO4) 100 mg/kg every 8 hours
Trial: 18343748
Drug: Azithromycin 1
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1 g once daily for 3 days
Trial: 18343748
Drug: Amoxicillin-clavulanate 875/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate 875/125 mg twice daily for 7 days
Trial: 14712970
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg ginger extract (EV.EXT35; equivalent to 1.5 g of dried ginger) given four times per day for 4 days
Trial: 9218089
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg 30 min before meals)
Trial: 9218089
Drug: Erythromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (250 mg 60 min before meals)
Trial: 29627268
Drug: Communication intervention
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Communication intervention using specific lexical formulations ('do you have 'any' vs. 'some' other concerns?')
Trial: 26950204
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of TA-65 (250 U)
Trial: 26950204
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of TA-65 (1000 U)
Trial: 19368096
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg daily for 6 months
Trial: 22864277
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg daily for 6 months
Trial: 12202120
Drug: Intraarticular hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular hyaluronic acid (20mg hyaluronic acid/2ml Hyalart) administered via five injections (one injection per week)
Trial: 7813259
Drug: PCP score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCP score (PCPSc) assessed on treatment days D0, D3, D7, D14, and D21
Trial: 7813259
Drug: LDH levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDH levels during treatment
Trial: 22706414
Drug: Dimebon add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimebon add-on treatment
Trial: 20050336
Drug: Vancomycin plus
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin plus rifampicin (1 g intravenous every 12 hrs plus 300 mg twice daily by mouth)
Trial: 17296974
Drug: Oblimersen (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oblimersen (3 mg/kg/d as a 7-day continuous intravenous infusion) plus fludarabine (25 mg/m2/d) and cyclophosphamide (250 mg/m2/d) for 3 days, for up to six cycles.
Trial: 17296974
Drug: Fludarabine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (25 mg/m2/d) and cyclophosphamide (250 mg/m2/d) for 3 days (chemotherapy-only group).
Trial: 17950856
Drug: Epoetin treatment
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin treatment (control)
Trial: 15572737
Drug: Olanzapine (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5-20 mg/day) combined with ongoing lithium or valproate
Trial: 15572737
Drug: Olanzapine co-therapy
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine co-therapy
Trial: 11153292
Drug: Ketorolac 10.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 10.5 mg subcutaneously at the end of surgery followed by a subcutaneous infusion of 1.75 mg/h for 24 to 36 hours
Trial: 1585039
Drug: Scheduled suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled suppository use
Trial: 30008080
Drug: Animated instructions
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animated instructions on tablets
Trial: 27090301
Drug: Ketamine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (single sub-anesthetic dose)
Trial: 25650044
Drug: High-volume CVVH
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume CVVH (4000 mL/h)
Trial: 25650044
Drug: Low-volume CVVH
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume CVVH (2000 mL/h)
Trial: 25650044
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (before treatment)
Trial: 25650044
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (after treatment)
Trial: 18852183
Drug: Blood pressure-lowering
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure-lowering treatment (including angiotensin-converting enzyme inhibitors, calcium antagonists, angiotensin receptor blockers, diuretics/beta-blockers)
Trial: 10732745
Drug: Nine cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine cycles of dose-escalated FEC (fluorouracil, epirubicin, and cyclophosphamide)